Published on May 21, 2010 at 9:22 AM
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.
“Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)”
Surasak Phuphanich, M.D., Director of the neuro-oncology program at the Cedars-Sinai Medical Center and the study's lead investigator, will present the poster titled, "Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)", on Sunday, June 6th.
The abstract released by ASCO today incorrectly states that "The median progression-free survival time in this group was 13.7 months and RT/TMZ regimen 6.9 months (EORTC/NCIC)". This should have been as follows: The median progression-free survival time in the newly diagnosed patients was 17.7 months compared to RT/TMZ regimen of 6.9 months (EORTC/NCIC).
SOURCE ImmunoCellular Therapeutics, Ltd.
f7675209-8918-442d-b4d0-3c82e241a3c9|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Antibody, Biotechnology, Brain, Cancer, Cell, Dendritic Cell, Glioblastoma, Immunotherapy, Lung Cancer, Monoclonal Antibody, Multiple Myeloma, Oncology, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Vaccine